Business
Notice of AGM
Physiomics PLC announced that its Annual General Meeting (AGM) will be held on November 18, 2025, at 10:30 a.m. The meeting will take place at Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB. Shareholders will receive either printed copies of the Notice of AGM and accompanying materials or a notification that these documents are available on the company's website, based on their registrar preferences. The Notice of AGM, detailing the resolutions to be proposed, along with the Company's Annual Report and Accounts, will be accessible on the Physiomics website. Disclaimer*
About this update from Physiomics Plc
17 October 2025 Physiomics plc ("Physiomics" or the "Company") Notice of AGM Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to provide notice of the Company's Annual General Meeting ("AGM"). The AGM will be held at 10.30 a.m. on 18 November 2025 at Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB. Shareholders will shortly be sent either printed copies of the Notice of AGM and accompanying materials or a letter notifying them that they are available on the Company's website, depending on the preferences they have expressed to the Company's registrar. A copy of the Notice of AGM, containing further details of the resolutions to be proposed at the meeting, as well as a copy of the Company's Annual Report and Accounts, will be made available today on the Company's website at www.physiomics.co.uk/investors/corporate-documents/ . For more information about Physiomics and its services, please visit www.physiomics.co.uk . Enquiries: Physiomics plc Dr Peter Sargent, CEO +44 (0)1235 841575 Hybridan LLP (Broker) Claire Louise Noyce +44 (0) 203 764 2341 Strand Hanson Ltd (NOMAD) James Dance & James Bellman +44 (0)20 7409 3494 Notes to Editor About Physiomics Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 140 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.